All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
“How I treat” post-transplant relapse of AML
Bookmark this article
|
Allo-HCT is among the principal curative treatment approaches for AML, but the prognosis remains poor for patients who relapse after transplantation.1 Treatment approaches for post-transplantation relapse are highly individualized and are informed by disease genomics and biology, the clinical status of a patient at relapse, and the interval between transplantation and relapse.1 A “how I treat” case series published in Blood by Gooptu et al.1 discussed treatment approaches at early, late, and incipient relapse of AML after allo-HCT. |
| Key learnings |
| Treatment considerations for early relapse include tapering IS, chemotherapy or targeted therapy based on patient fitness and genomic profile, and consolidation with cellular therapy, such as, DLI or a second HCT. |
| Treatment considerations for isolated EM relapse include addressing targetable mutations, assessing disease burden to decide on immediate chemotherapy vs immunotherapies such as checkpoint inhibitors, the need for localized radiation/CNS-directed therapy, and consideration of consolidative DLI/second HCT. |
| In cases of molecular relapse, high-risk patients should be prioritized for clinical trials of conditioning intensification, post-HCT maintenance, peri-transplant adoptive cellular therapies, or novel graft engineering to enhance GVL. Outside of trials, approaches include combining IS tapering, HMAs, and DLI (lower doses in prophylactic/preemptive setting recommended by EBMT). |
| Future directions involve improving relapse prediction and prognostication based on MRD status, exploring novel agents and prioritizing clinical trial enrollment, and discussing comfort-focused care, especially for frail patients. |
Abbreviations: Allo-HCT, allogeneic hematopoietic stem-cell transplantation; AML, acute myeloid leukemia; CNS, central nervous system; DLI, donor lymphocyte infusions; EBMT, European Society for Blood & Marrow Transplantation; EM, extramedullary; GVL, graft vs leukemia; HCT, hematopoietic stem cell transplantation; HMA, hypomethylating agent; IS, immunosuppression; MRD, measurable residual disease.
- Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HCT. Blood. 2024. Online ahead of print. DOI: 1182/blood.2024025705.
Your opinion matters
42 votes - 8 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox